Boston Scientific raises its 2025 profit outlook to $2.95-$2.99 per share due to strong Q2 performance driven by Farapulse PFA system. Total Q2 sales exceed $5bn, with cardiovascular unit leading at $3.34bn. Competition in PFA space from Medtronic and J&J. FDA approved Farapulse in 2024. (Word count: 49)

CEO praises Q2 as excellent, with substantial growth in urology and peripheral intervention units. CFO notes boost in sales from increased surgical procedures, offsetting concerns about healthcare spending. Anticipates $100m headwind from tariffs. GlobalData reports US preference for Farapulse over PulseSelect. J&J sees 7.3% rise in Medtech unit. (Word count: 50)

Read more at Yahoo Finance: Boston Scientific lifts 2025 outlook following 29% Q2 cardiovascular profit rise